Gynecologic Oncology

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Dostarlimab plus carboplatin/paclitaxel improved overall survival vs placebo plus chemotherapy in primary advanced or recurrent endometrial cancer.

The addition of pembrolizumab to chemotherapy led to a favorable overall survival benefit vs chemotherapy plus placebo in endometrial cancer.

Social determinants of health were associated with geographical variations in the rates of cervical cancer in the United States.

The KEYNOTE-A18 trial met its coprimary end point of improved OS with pembrolizumab plus concurrent chemoradiotherapy in high-risk cervical cancer.

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

The National Institute for Health and Care Excellence recommends the approval of dostarlimab plus chemotherapy for advanced/recurrent endometrial cancer.

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.

Michael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

The MAA seeking the approval of tisotumab vedotin in select patients with recurrent or metastatic cervical cancer has been validated by the EMA.